Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I, Rabitsch, W., Kwong, Y-L, Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., Martinez-Lopez, J., Mueller, A. M. S., Maziarz, R. T., McGuirk, J. P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., del Corral, C., Andreola, G., Masood, A., Schuster, S. J., Jaeger, U., Borchmann, P. and Westin, J. R. (2022). Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N. Engl. J. Med., 386 (7). S. 629 - 640. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A. and Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. Oncol. Res. Treat., 37. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262

Stilgenbauer, S., Hallek, M. J., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Coiffier, B., O'Brien, S. M., Tausch, E., Sharman, J. P., Ruppert, S., Schuster, A. and Kroenig, H. (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262

This list was generated on Wed May 22 03:23:25 2024 CEST.